General Information
Madrigal NAFLD MGL-3196-14
A 52-Week Phase 3 Study of Resmetirom (MGL-3196) in Non alcoholic Fatty Liver Disease (NAFLD) Patients with Hyperlipidemia to Reduce LDL-Cholesterol (MAESTRO NAFLD-1)”
| Protocol | MGL-3196-14 |
|---|---|
| Identifier | |
| UID | 212124cb-29c0-4c59-b475-78d98e5b3474 |
| Status | Done - Archived |
| Phase | 3 |
| Category | Fatty Liver / Adult |
| Launch Year | 2020 |
| NCT Number | - |
| Created | 2019-11-20 12:57 |
| Last Updated | 2023-02-20 22:49 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2021-08-21 | No |
| Enrollment Open | 2020-03-06 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2020-02-07 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2022-07-20 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | Miss, Salomon | SMiss | No |
| Coordinator | Valenzuela, Louisito | LValenzuela | No |
| Regulatory | Ramirez, Claudia | CRamirez | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Madrigal Pharmaceuticals |
|---|---|
| Division | Madrigal Pharmaceuticals |
| Team | Madrigal Pharmaceuticals |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | PRA (NC) |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
